Illumina, Inc. (ILMN)

Illumina's stock price has fluctuated over the past six months, with a decline of 13.89% from November 25, 2024, to November 21, 2025. Key events include the divestiture of GRAIL, the acquisition of SomaLogic, Q2 CY2025 earnings that beat revenue expectations but saw a negative market reaction due to declining sales and operating margins, Q3 2025 earnings that exceeded estimates and raised full-year guidance, and leadership changes.

Illumina's products and services exhibit some demand seasonality. The company anticipates usual seasonality in instrument purchases and a seasonal increase in ordering activity and backlog build for consumables in the fourth quarter. This typically signals positive underlying sequencing activity for the remainder of the year.

Illumina, Inc. is a biotechnology company focused on developing, manufacturing, and marketing integrated systems for genetic variation and biological function analysis. It is a global leader in DNA sequencing and array-based technologies, offering instruments, reagents, and software solutions. Revenue is generated from Product and Service segments, with the clinical segment being a primary growth driver.

Illumina has a global presence in over 155 to 165 countries, serving genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, and biotechnology firms. Its headquarters are in San Diego, California, with additional facilities across the United States and internationally in Singapore, Israel, China, Korea, and Japan. Products are distributed directly in North America, Europe, Latin America, and the Asia-Pacific region, and through distributors elsewhere.

Illumina maintains a strong brand reputation for quality and innovation in the biotechnology sector. However, the acquisition and subsequent divestiture of GRAIL negatively impacted its brand image and management's judgment. Despite this, the company remains a key player in the next-generation sequencing ecosystem.

Illumina's ownership is heavily concentrated among institutional investors, who control approximately 85.00% to 89.42% of the company's stock. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Capital World Investors, and State Street Global Advisors, Inc. Insiders hold a relatively small stake, typically around 2.6% of the stock.